补充双歧杆菌益生菌对血糖的影响:临床前动物模型和临床证据的系统综述和荟萃分析。

IF 8 1区 医学 Q1 NUTRITION & DIETETICS
Emily P. Van Syoc , Janhavi Damani , Zachary DiMattia , Erika Ganda , Connie J. Rogers
{"title":"补充双歧杆菌益生菌对血糖的影响:临床前动物模型和临床证据的系统综述和荟萃分析。","authors":"Emily P. Van Syoc ,&nbsp;Janhavi Damani ,&nbsp;Zachary DiMattia ,&nbsp;Erika Ganda ,&nbsp;Connie J. Rogers","doi":"10.1016/j.advnut.2023.10.009","DOIUrl":null,"url":null,"abstract":"<div><p>Probiotic supplementation is a potential therapeutic for metabolic diseases, including obesity, metabolic syndrome (MetS), and type 2 diabetes (T2D), but most studies deliver multiple species of bacteria in addition to prebiotics or oral pharmaceuticals. This may contribute to conflicting evidence in existing meta-analyses of probiotics in these populations and warrants a systematic review of the literature to assess the contribution of a single probiotic genus to better understand the contribution of individual probiotics to modulate blood glucose. We conducted a systematic review and meta-analysis of animal studies and human randomized controlled trials (RCTs) to assess the effects of <em>Bifidobacterium</em> (<em>BF</em>) probiotic supplementation on markers of glycemia. In a meta-analysis of 6 RCTs, <em>BF</em> supplementation had no effect on fasting blood glucose {FBG; mean difference [MD] = −1.99 mg/dL [95% confidence interval (CI): −4.84, 0.86], <em>P</em> = 0.13}, and there were no subgroup differences between subjects with elevated FBG concentrations and normoglycemia. However, <em>BF</em> supplementation reduced FBG concentrations in a meta-analysis comprised of studies utilizing animal models of obesity, MetS, or T2D [<em>n =</em> 16; MD = −36.11 mg/dL (CI: −49.04, −23.18), <em>P</em> &lt; 0.0001]. Translational gaps from animal to human trials include paucity of research in female animals, <em>BF</em> supplementation in subjects that were normoglycemic, and lack of methodologic reporting regarding probiotic viability and stability. More research is necessary to assess the effects of <em>BF</em> supplementation in human subjects with elevated FBG concentrations. Overall, there was consistent evidence of the efficacy of <em>BF</em> probiotics to reduce elevated FBG concentrations in animal models but not clinical trials, suggesting that <em>BF</em> alone may have minimal effects on glycemic control, may be more effective when combined with multiple probiotic species, or may be more effective in conditions of hyperglycemia rather than elevated FBG concentrations.</p></div>","PeriodicalId":7349,"journal":{"name":"Advances in Nutrition","volume":"15 1","pages":"Article 100137"},"PeriodicalIF":8.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2161831323013984/pdfft?md5=864e5955206d5fa6da355e38ca2d7f27&pid=1-s2.0-S2161831323013984-main.pdf","citationCount":"0","resultStr":"{\"title\":\"The Effects of Bifidobacterium Probiotic Supplementation on Blood Glucose: A Systematic Review and Meta-Analysis of Animal Models and Clinical Evidence\",\"authors\":\"Emily P. Van Syoc ,&nbsp;Janhavi Damani ,&nbsp;Zachary DiMattia ,&nbsp;Erika Ganda ,&nbsp;Connie J. Rogers\",\"doi\":\"10.1016/j.advnut.2023.10.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Probiotic supplementation is a potential therapeutic for metabolic diseases, including obesity, metabolic syndrome (MetS), and type 2 diabetes (T2D), but most studies deliver multiple species of bacteria in addition to prebiotics or oral pharmaceuticals. This may contribute to conflicting evidence in existing meta-analyses of probiotics in these populations and warrants a systematic review of the literature to assess the contribution of a single probiotic genus to better understand the contribution of individual probiotics to modulate blood glucose. We conducted a systematic review and meta-analysis of animal studies and human randomized controlled trials (RCTs) to assess the effects of <em>Bifidobacterium</em> (<em>BF</em>) probiotic supplementation on markers of glycemia. In a meta-analysis of 6 RCTs, <em>BF</em> supplementation had no effect on fasting blood glucose {FBG; mean difference [MD] = −1.99 mg/dL [95% confidence interval (CI): −4.84, 0.86], <em>P</em> = 0.13}, and there were no subgroup differences between subjects with elevated FBG concentrations and normoglycemia. However, <em>BF</em> supplementation reduced FBG concentrations in a meta-analysis comprised of studies utilizing animal models of obesity, MetS, or T2D [<em>n =</em> 16; MD = −36.11 mg/dL (CI: −49.04, −23.18), <em>P</em> &lt; 0.0001]. Translational gaps from animal to human trials include paucity of research in female animals, <em>BF</em> supplementation in subjects that were normoglycemic, and lack of methodologic reporting regarding probiotic viability and stability. More research is necessary to assess the effects of <em>BF</em> supplementation in human subjects with elevated FBG concentrations. Overall, there was consistent evidence of the efficacy of <em>BF</em> probiotics to reduce elevated FBG concentrations in animal models but not clinical trials, suggesting that <em>BF</em> alone may have minimal effects on glycemic control, may be more effective when combined with multiple probiotic species, or may be more effective in conditions of hyperglycemia rather than elevated FBG concentrations.</p></div>\",\"PeriodicalId\":7349,\"journal\":{\"name\":\"Advances in Nutrition\",\"volume\":\"15 1\",\"pages\":\"Article 100137\"},\"PeriodicalIF\":8.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2161831323013984/pdfft?md5=864e5955206d5fa6da355e38ca2d7f27&pid=1-s2.0-S2161831323013984-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Nutrition\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2161831323013984\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Nutrition","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2161831323013984","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0

摘要

益生菌补充剂是治疗代谢性疾病的潜在药物,包括肥胖、代谢综合征(MetS)和2型糖尿病(T2D),但大多数研究除了提供益生元或口服药物外,还提供多种细菌。这可能会导致这些人群中现有益生菌荟萃分析中存在相互矛盾的证据,并保证对文献进行系统审查,以评估单个益生菌属的贡献,从而更好地了解单个益生菌对调节血糖的贡献。我们对动物研究和人类随机对照试验(RCT)进行了系统综述和荟萃分析,以评估补充双歧杆菌(BF)益生菌对血糖标志物的影响。在一项对六项随机对照试验的荟萃分析中,补充BF对空腹血糖没有影响(FBG;平均差(MD)=-1.99 mg/dL[95%置信区间(CI):-4.84,0.86],P=0.13),并且FBG升高和血糖正常的受试者之间没有亚组差异。然而,在一项荟萃分析中,BF补充剂降低了FBG,该荟萃分析包括利用肥胖、代谢综合征或T2D动物模型的研究(n=16;MD=36.11mg/dL[CI:-49.04,-23.18],P<0.0001)。从动物到人类试验的转化差距包括缺乏对雌性动物的研究,在血糖正常的受试者中补充BF,以及缺乏关于益生菌活力和稳定性的方法学报告。需要更多的研究来评估补充BF对FBG升高的人类受试者的影响。总的来说,在动物模型中,有一致的证据表明BF益生菌可以降低FBG升高,但在临床试验中没有,这表明单独的BF可能对血糖控制的影响最小,与多种益生菌组合可能更有效,或者在高血糖情况下可能比FBG升高更有效。意义陈述:这是首次对益生菌属双歧杆菌对血糖影响的系统综述和荟萃分析,不包括多属益生菌混合物或益生元的额外使用或抗糖尿病治疗。该综述还讨论了动物研究的结果,以进一步了解在肥胖、代谢综合征和2型糖尿病的情况下,补充双歧杆菌如何影响血糖。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Effects of Bifidobacterium Probiotic Supplementation on Blood Glucose: A Systematic Review and Meta-Analysis of Animal Models and Clinical Evidence

Probiotic supplementation is a potential therapeutic for metabolic diseases, including obesity, metabolic syndrome (MetS), and type 2 diabetes (T2D), but most studies deliver multiple species of bacteria in addition to prebiotics or oral pharmaceuticals. This may contribute to conflicting evidence in existing meta-analyses of probiotics in these populations and warrants a systematic review of the literature to assess the contribution of a single probiotic genus to better understand the contribution of individual probiotics to modulate blood glucose. We conducted a systematic review and meta-analysis of animal studies and human randomized controlled trials (RCTs) to assess the effects of Bifidobacterium (BF) probiotic supplementation on markers of glycemia. In a meta-analysis of 6 RCTs, BF supplementation had no effect on fasting blood glucose {FBG; mean difference [MD] = −1.99 mg/dL [95% confidence interval (CI): −4.84, 0.86], P = 0.13}, and there were no subgroup differences between subjects with elevated FBG concentrations and normoglycemia. However, BF supplementation reduced FBG concentrations in a meta-analysis comprised of studies utilizing animal models of obesity, MetS, or T2D [n = 16; MD = −36.11 mg/dL (CI: −49.04, −23.18), P < 0.0001]. Translational gaps from animal to human trials include paucity of research in female animals, BF supplementation in subjects that were normoglycemic, and lack of methodologic reporting regarding probiotic viability and stability. More research is necessary to assess the effects of BF supplementation in human subjects with elevated FBG concentrations. Overall, there was consistent evidence of the efficacy of BF probiotics to reduce elevated FBG concentrations in animal models but not clinical trials, suggesting that BF alone may have minimal effects on glycemic control, may be more effective when combined with multiple probiotic species, or may be more effective in conditions of hyperglycemia rather than elevated FBG concentrations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advances in Nutrition
Advances in Nutrition 医学-营养学
CiteScore
17.40
自引率
2.20%
发文量
117
审稿时长
56 days
期刊介绍: Advances in Nutrition (AN/Adv Nutr) publishes focused reviews on pivotal findings and recent research across all domains relevant to nutritional scientists and biomedical researchers. This encompasses nutrition-related research spanning biochemical, molecular, and genetic studies using experimental animal models, domestic animals, and human subjects. The journal also emphasizes clinical nutrition, epidemiology and public health, and nutrition education. Review articles concentrate on recent progress rather than broad historical developments. In addition to review articles, AN includes Perspectives, Letters to the Editor, and supplements. Supplement proposals require pre-approval by the editor before submission. The journal features reports and position papers from the American Society for Nutrition, summaries of major government and foundation reports, and Nutrient Information briefs providing crucial details about dietary requirements, food sources, deficiencies, and other essential nutrient information. All submissions with scientific content undergo peer review by the Editors or their designees prior to acceptance for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信